Neuroprotective activity of metabotropic glutamate receptor ligands

Advances in Experimental Medicine and Biology

Volumn 513, Issue , 2002, Pages 197-223

  Flor, Peter J ^a   Battaglia, Giuseppe ^b   Nicoletti, Ferdinando ^b,c   Gasparini, Fabrizio ^a   Bruno, Valeria ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b IRCCS NEUROMED   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; BAY 367620; EGLUMETAD; GLUTAMIC ACID DERIVATIVE; LIGAND; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; BRAIN INJURY; BRAIN ISCHEMIA; DRUG PENETRATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; EPILEPSY; HUNTINGTON CHOREA; KNOCKOUT MOUSE; MOUSE; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW;

ANIMALS; CELLS, CULTURED; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; HUMANS; LIGANDS; MOLECULAR STRUCTURE; NEURODEGENERATIVE DISEASES; NEURONS; NEUROPROTECTIVE AGENTS; PROTEIN ISOFORMS; RECEPTORS, METABOTROPIC GLUTAMATE; SYNAPSES;

ANIMALIA;

EID: 0345894319     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (152)

1. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994; 330:613-622.
2. Hollmann M, Heinemann S. Cloned glutamate receptors. Annu Rev Neurosci 1994; 17:31-108.
3. Dingledine R, Borges K, Bowie D et al. The glutamate receptor ion channels. Pharmacol Rev 1999; 51:7-61.
4. Tanabe Y, Masu M, Ishii T et al. A family of metabotropic glutamate receptors. Neuron 1992; 8:169-179.
5. Nakanishi S. Metabotropic glutamate receptors: Synaptic transmission, modulation, and plasticity. Neuron 1994, 13:1031-1037.
6. Conn PJ, Pin J-P. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 1997; 37:205-237.
7. Laurie DJ, Boddeke HW, Hiltscher R et al. HmGluld, a novel splice variant of the human type I metabotropic glutamate receptor. Eur J Pharmacol 1996; 296:R1-R3.
8. Flor PJ, Gomeza J, Tones MA et al. The C-terminal domain of the mGluR1 metabotropic glutamate receptor affects sensitivity to agonists. J Neurochem 1996; 67:58-63.
9. Schoepp DD, Jane DE, Monn AJ. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 1999; 38:1431-1476.
10. Iversen L, Mulvihill E, Haldeman B et al. Changes in metabotropic glutamate receptor mRNA levels following global ischemia: increase of a putative presynaptic subtype (mGluR4) in highly vulnerable rat brain areas. J Neurochem 1994; 63:626-633.
11. Minakami R, Katsuki F, Yamamoto T et al. Molecular cloning and the functional expression of two isoforms of human metabotropic glutamate receptor subtype 5. Biochem Biophys Res Commun 1994; 199:1136-1143.
12. Joly C, Gomeza J, Brabet I et al. Molecular, functional, and pharmacological characterization of the metabotropic glutamate receptor type 5 splice variants: Comparison with mGluR1. J Neurosci 1995; 15:3970-81.
13. Flor PJ, van der Putten H, R egg D et al. A novel splice variant of a metabotropic glutamate receptor, human mGluR7b. Neuropharmacology 1997; 36:153-159.
14. Corti C, Rimland JM, Corsi M et al. Isolation and analysis of splice variants of the rat metabotropic glutamate receptors, mGluR7 and mGluR8. Soc Neurosci Abstr 1997; 23:939.
15. Okamoto N, Hori S, Akazawa C et al. Molecular characterization of a new metabotropic glutamate receptor mGluR7 coupled to inhibitory cyclic AMP signal transduction. J Biol Chem 1994; 269:1231-1236.
16. Duvoisin RM, Zhang C, Ramonell K. A novel metabotropic glutamate receptor expressed in the retina and olfactory bulb. J Neurosci 1995; 15:3075-3083.
17. Flor PJ, Lindauer K, P ttner I et al. Molecular cloning, functional expression and pharmacological characterization of the human metabotropic glutamate receptor type 2. Eur J Neurosci 1995; 7:622-629.
18. Flor PJ, Lukic S, R egg D et al. Molecular cloning, functional expression and pharmacological characterization of the human metabotropic glutamate receptor type 4. Neuropharmacology 1995; 34:149-155.
19. Johansen PA, Chase LA et al. Type 4a metabotropic glutamate receptor: identification of new potent agonists and differentiation from the L-(+)-2-amino-4-phosphonobutanoic acid-sensitive receptor in the lateral perforant pathway in rats. Mol Pharmacol 1995; 48:140-149.
20. Monn JA, Valli MJ, Massey SM et al. Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): A potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem 1997; 40:528-537.
21. Gasparini F, Bruno V, Battaglia G et al. (R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist is anticonvulsive and neuroprotective in vivo. J Pharmacol Exp Ther 1999; 290:1678-1687.
22. Baude A, Nusser Z, Roberts JD et al. The metabotropic glutamate receptor (mGluR1 alpha) is concentrated at perisynaptic membrane of neuronal subpopulations as detected by immunogold reaction. Neuron 1993; 11:771-787.
23. Shigemoto R, Kinoshita A, Wada E et al. Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J Neurosci 1997; 17:7503-7522.
24. Petralia RS, Wang YX, Niedzielski AS et al. The metabotropic glutamate receptors, mGluR2 and mGluR3, show unique postsynaptic, presynaptic and glial localizations. Neuroscience 1996; 71:949-976.
25. Lujan R, Roberts JD, Shigemoto R et al. Differential plasma membrane distribution of metabotropic glutamate receptors mGluR1 alpha, mGluR2 and mGluR5, relative to neurotransmitter release sites. J Chem Neuroanat 1997; 13:219-241.
26. Ohishi H, Shigemoto R, Nakanishi S et al. Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: An in situ hybridization study. J Comp Neurol 1993; 335:252-266.
27. Ohishi H, Ogawa-Meguro R, Shigemoto R et al. Immunohistochemical localization of metabotropic glutamate receptors, mGluR2 and mGluR3, in rat cerebellar cortex. Neuron 1994; 13:55-66.
28. Mineff E, Valtschanoff J. Metabotropic glutamate receptors 2 and 3 expressed by astrocytes in rat ventrobasal thalamus. Neurosci Lett 1999; 270:95-98.
29. Trombley PQ, Westbrook GL. L-AP4 inhibits calcium currents and synaptic transmission via a G-protein-coupled glutamate receptor. J Neurosci 1992; 12:2043-2050.
30. Br uner-Osborne H, Egebjerg J, Nielsen EO et al. Ligands for glutamate receptors: Design and therapeutic prospects. J Med Chem 2000; 43:2609-2645.
31. Br uno V, Battaglia G, Kingston A et al. Neuroprotective activity of the potent and selective mGlu1a metabotropic glutamate receptor antagonist, (+)-2-methyl-4-carboxyphenylglycine (LY367385): Comparison with LY367366, a broader spectrum antagonist with equal affinity for mGlu1a and mGlu5 receptors. Neuropharmacology 1999; 38:199-207.
32. Gasparini F, Lingenh hl K, Stoehr N, et al. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 1999; 38:1493-1503.
33. Litschig S, Gasparini F, Rueegg D, et al. CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol Pharmacol 1999; 55:453-461.
34. Carroll FY, Stolle A, Beart PM, et al. BAY36-7620: A potent non-competitive mGlu1 receptor antagonist with inverse agonist activity. Mol Pharmacol 2001; 59:965-973.
35. Bruno V, Copani A, Kn pfel T, et al. Activation of metabotropic glutamate receptors coupled to inositol phospholipid hydrolysis amplifies NMDA-induced neuronal degeneration in cultured cortical cells. Neuropharmacology 1995; 34:1089-1098.
36. Bruno V, Battaglia G, Copani A, et al. Activation of class II or class III metabotropic glutamate receptors protects cultured cortical neurons against excitotoxic degeneration. Eur J Neurosci 1995; 7:1906-1913.
37. Brabet I, Parmentier M-L, De Colle C, et al. Comparative effect of L-CCG-I, DCG-IV and_-carboxyl-L-glutamate on all cloned metabotropic glutamate receptor subtypes. Neuropharmacology 1998; 37:1043-1051.
38. Wroblewska B, Wroblewski JT, Pschenichkin S, et al. N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells. J Neurochem 1997; 69:174-181.
39. M ller T, De Vry, J, Schreiber R, et al. BAY 36-7620, a selective metabotropic glutamate receptor1 antagonist with anticonvulsant and neuroprotective properties. Soc Neurosci Abs 2000; 26:1650.
40. Annoura H, Fukunaga A, Uesugi M, et al. A novel class of antagonists for metabotropic glutamate receptors, 7-(hydroxyimino)cyclopropa[b]chromen-Ia-carboxylates. Bioorganic Medical Chemistry Letters 1996; 6:7763-7766.
41. Monn JA, Valli MJ, Massey SM, et al. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): Identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. J Med Chem 1999; 42:1027-1040.
42. Spooren WPJM, Gasparini F, Salt TE, et al. Novel allosteric antagonists shed light on mglu5 receptors and CNS disorders. Trends Pharmacol Sci 2001; 22:in press.
43. Walker K, Bowes M, Panesar M, et al. Metabotropic glutamate receptor subtype 5 (mGlu5) and nociceptive function, I. Selective blockade of mGlu5 receptors in models of acute, persistent and chronic pain. Neuropharmacology 2001; 40:1-9.
44. Bruno V, Battaglia G, Ksiazek I, et al. Selective activation of mGlu4 metabotropic glutamate receptors is protective against excitotoxic neuronal death. J Neurosci 2000; 20:6413-6420.
45. Henrich-Noack P, Flor PJ, Sabelhaus CF, et al. Distinct influence of the group III metabotropic glutamate receptor agonist (R,S)-4-phosphonophenylglycine [(R,S)-PPG] on different forms of neuronal damage. Neuropharmacology 2000; 39:911-917.
46. Nicoletti F, Bruno V, Catania MV, et al. Group-I metabotropic glutamate receptors: Hypotheses to explain their dual role in neurotoxicity and neuroprotection. Neuropharmacology 1999; 38:1477-1484.
47. Kawabata S, Tsutsumi R, Kohara A, et al. Control of calcium oscillations by phosphorylation of metabotropic glutamate receptors. Nature 1996; 383:89-92.
48. Pin JP, Duvoisin R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology 1995; 34:1-26.
49. Chuang SC, Bianchi R, Wong RK. Group-I mGluR activation turns on a voltage-gated inward current in hippocampal pyramidal cells. J. Neurophysiol. 2000; 83:2844-2853.
50. Pisani A, Calabresi P, Centonze D, et al. Enhancement of NMDA responses by group-I metabotropic glutamate receptor activation in striatal neurones. Br J Pharmacol 1997; 120:1007-1014.
51. Jia Z, Lu Y, Henderson J, et al. Selective abolition of the NMDA component of long-term potentiation in mice lacking mGluR5. Learn. Mem. 1998; 5:331-343.
52. Ugolini A, Corsi M, Bordi F. Potentiation of NMDA and AMPA responses by the specific mGluR5 agonist CHPG in spinal cord motoneurons. Neuropharmacology 1999; 38:1569-1576.
53. Awad H, Hubert GW, Smith Y, et al. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci 2000; 20:7871-7879.
54. Doherty AJ, Palmer MJ, Bortolotto ZA, et al. A novel, competitive mGlu(5) receptor antagonist (LY344545) blocks DHPG-induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices. Br J Pharmacol 2000; 131:239-244.
55. Salt TE, Binns KE. Contributions of mGlu1 and mGlu5 receptors to interactions with N-methyl-D-aspartate receptor-mediated responses and nociceptive sensory responses of rat thalamic neurons. Neuroscience 2000; 100:375-380.
56. Alagarsamy S, Marino MJ, Rouse ST, et al. Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems. Nature Neurosci 1999; 2:234-240.
57. De Blasi A, Conn PJ, Pin JP, et al. Molecular determinant of metabotropic glutamate receptor signaling. Trends Pharmacol Sci 2001; 22:114-120.
58. Tu JC, Xiao B, Naisbitt S, et al. Coupling of mGluR/Homer and PSD-95 coplexes by the Shank family of postsynaptic density proteins. Neuron 1999; 23:583-592.
59. Pizzi M, Boroni F, Moraitis K, et al. Reversal of glutamate excitotoxicity by activation of PKC-associated metabotropic glutamate receptors in cerebellar granule cells relies on NR2C subunit expression. Eur J Neurosci 1999; 11:1-8.
60. Herrero I, Miras-Portugal MT, Sanchez-Prieto J. Positive feed-back of glutamate exocytosis by metabotropic presynaptic receptor stimulation. Nature 1992; 360:163-166.
61. Herrero I, Miras-Potugal MT, Sanchez-Prieto J. Rapid desensitization of the presynaptic metabotropic receptor that facilitates glutamate exocytosis. Eur J Neurosci 1994; 6:115-120.
62. Herrero I, Miras-Portugal MT, Sanchez-Prieto J. Functional switch from facilitation to inhibition in the presynapticcontrol of glutamate release by metabotropic glutamate receptors. J Biol Chem 1998; 273:1951-1958.
63. Rodriguez-Moreno A, Sistiaga A, Lerma J, et al. Switch from facilitation to inhibition of excitatory synaptic transmission by the desensitization of group-I mGluRs in the rat hippocampus. Neuron 1998; 21:1477-1486.
64. Sistiaga A, Herrero I, Conquet F, et al. The metabotropic glutamate receptor 1 is not involved in the facilitation of glutamate release in cerebro-cortical nerve terminals. Neuropharmacology 1998; 3:1485-1492.
65. Sistiaga A, Sanchez-Prieto J. Protein phosphatase 1 and 2A inhibitors prolong the switch in the control of glutamate release by group I metabotropic glutamate receptors: characterization of the inhibitory pathway. J Neurochem 2000; 75:1566-1574.
66. Bruno V, Battaglia G, Copani A, et al. An activity-dependent switch from facilitation to inhibition in the control of excitotoxicity by group-I metabotropic glutamate receptors. Eur. J. Neurosci. 2001; 13:1469-1478.
67. Ango F, Pin JP, Tu JC, et al. Dendritic and axonal targeting of type 5 metabotropic glutamate receptor is regulated by homer 1 protein and neuonal excitation. J Neurosci 2000; 20:8710-8716.
68. Lee JM, Zipfel GJ, Choi DW. The changing landscape of ischemic brain injury mechanisms. Nature 1999; 399 (Suppl.):A7-A14.
69. Allen JW, Knoblach SM, Faden AI. Activation of group I metabotropic glutamate receptors reduces neuronal apoptosis but increases necrotic cell death in vitro. Cell Death Diff 2000; 7:470-476.
70. Strasser U, Lobner D, Berhens MM, et al. Antagonists of group-I mGluRs attenuate exicitotoxic neuronal death in cortical cultures. Europ J Neurosci 1998; 10:2848-2855.
71. Battaglia G, Bruno V, Pisani A, et al. Selective blockade of type-I metabotropic glutamate receptors induces neuroprotection by enhancing GABAergic transmission. Mol Cell Neurosci 2001; in press.
72. Orlando LR, Alsdorf SA, Penney JB Jr, et al. The role of group I and group II metabotropic glutamate receptors in modulation of striatal NMDA and quinolinic acid toxicity. Exp. Neurol. 2001; 167:196-204.
73. Pellegrini-Giampietro DE, Cozzi A, Peruginelli F, et al. 1-Aminoindan-1,5-dicarboxylic acid and (S)-(+)-2-(3′-carboxyicyclo(1.1.1.)pentyl)-glycine, two mGlu1 receptor-preferring antagonists, reduce neuronal death in in vitro and in vivo models of cerebral ischemia. Eur. J. Neurosci. 1999; 11:3637-3647.
74. Pellegrini-Giampietro DE, Peruginelli F, Meli E, et al. Protection with metabotropic glutamate 1 receptor antagonists in models of ischemic neuronal death: time-course and mechanisms. Neuropharmacol. 1999; 38:1607-1619.
75. Gereau IV RW, Conn PJ. Multiple presynaptic metabotropic glutamate receptors modulate excitatory and inhibitory synaptic transmission in hippocampal area CA1. J Neurosci 1995; 15:6879-6889.
76. Morishita W, Kirov SA, Alger BE. Evidence for metabotropic glutamate receptor activation in the induction of depolarization-induced suppression of inhibition in hippocampal CA1. J Neurosci 1998; 18:4870-4882.
77. Bushell TJ, Lee CC, Shigemoto R, et al. Modulation of synaptic transmission and differential localisation of mGluRs in cultured hippocampal autapses. Neuropharmacology 1999; 38:1553-1567.
78. Paquet M, Smith Y. Subsynaptic localization of group I metabotropic glutamate receptors at glutamatergic synapses in monkey striatum. Soc Neurosci Abs 2000; 26:740.13.
79. McNamara JO. Emerging insights into the genesis of epilepsy. Nature 1999; 399 (Suppl.):A15-A22.
80. Bruno V, Ksiazek I, Battaglia G, et al. Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective. Neuropharmacology 2000; 39:2223-2230.
81. O Leary DM, Movsesyan V, Vicini S, et al. Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism. Br J Pharmacol 2000; 131:1429-1437.
82. Copani A, Casabona G, Bruno V, et al. The metabotropic glutamate receptor mGlu5 controls the onset of developmental apoptosis in cultured cerebellar neurons. Eur J Neurosci 1998; 10:2173-2184.
83. Allen JW, Eldadah BA, Faden AI. Beta-amyloid-induced apoptosis of cerebelalr granule cells and cortical neurons: Exacerbation by selective inhibition of group-I metabotropic glutamate receptors. Neuropharmacology 1999; 38:1243-1252.
84. Bruno V, Copani A, Battaglia G, et al. Protective effect of the metabotropic glutamate receptor agonist, DCG-IV, against excitotoxic neuronal death. Eur J Pharmacol 1994; 256:109-112.
85. Bruno V, Sureda FX, Storto M, et al. The neuroprotective activity of group-II metabotropic glutamate receptors requires new protein synthesis and involves a glial-neuronal signaling. J Neurosci 1997; 17:1891-1897.
86. Bruno V, Battaglia G, Casabona G, et al. Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-beta. J Neuroscience 1998; 18:9594-9600.
87. Buisson A, Choi DW. The inibitory mGluR agonist, S-4-carboxy-3-hydroxy-phenylglycine selectively attenuates NMDA neurotoxicity and oxygen-glucose deprivation-induced neuronal death. Neuropharmacology 1995; 34:1081-1087.
88. Buisson A, Nicole O, Docagne F, et al. Up-regulation of a serine protease inhibitor in astrocytes mediates the neuroprotective activity of transforming growth factor-β1. FASEB J 1998; 12:1683-1691.
89. D Onofrio M, Cuomo L, Battaglia G, et al. Neuroprotection mediated by group-II metabotropic glutamate receptors involves the activation of the MAP kinase pathway and requires the induction of TGF-β1. J Neurochem 2001; in press.
90. Thomsen C, Bruno V, Nicoletti F, et al. (2S, 1 S,2 S,3 R)-2-(2-Carboxy-3-phenylcyclopropyl) glycine, a potent and selective antagonist of type 2 metabotropic glutamate receptors. Mol Pharmacol 1996; 50:6-9.
91. Battaglia G, Bruno V, Ngomba RT, et al. Selective activation of group-II metabotropic glutamate receptors is protective against excitotoxic neuronal death. Eur J Pharmacol 1998; 356:271-274.
92. Gottron F, Turetsky D, Choi D. SMI-32 antibody against non-phosphorylated neurofilaments identifies a subpopulation of cultured cortical neurons hypersensitive to kainate toxicity. Neurosci Lett 1995; 194:1-4.
93. Pizzi M, Fallacara C, Arrighi V, et al. Attenuation of excitatory amino acid toxicity by metabotropic glutamate receptor agonists and aniracetam in primary cultures of cerebellar granule cells. J Neurochem 1993; 61:683-689.
94. Ambrosini A, Bresciani L, Fracchia S, et al. Metabotropic glutamate receptors negatively coupled to adenylate cyclase inhibit N-methyl-D-aspartate receptor activity and prevent neurotoxicity in mesencephalic neurons in vitro. Mol Pharmacol 1995; 47:1057-1064.
95. Kingston AE, O Neill MJ, Bond A, et al. Neuroprotective action of novel and potent ligands of group-I and group-II metabotropic glutamate receptors. Ann NY Acad Sci 1999; 890:438-439.
96. Kingston AE, O Neill MJ, Lam A, et al. Neuroprotection by metabotropic glutamate receptor agonists: LY354740, LY379268 and LY389795. Eur J Pharmacol 1999; 377:155-165.
97. Behrens MM, Strasser U, Heidinger V, et al. Selective activation of group II mGluRs with LY354740 does not prevent neuronal excitotoxicity. Neuropharmacology 1999; 38:1621-1630.
98. Copani A, Bruno V, Battaglia G, et al. Activation of metabotropic glutamate receptors protects cultured neurons against apoptosis induced by beta-amyloid peptide. Mol Pharmacol 1995; 47:890-897.
99. Copani A, Bruno V, Barresi V, et al. Activation of metabotropic glutamate receptors prevents neuronal apoptosis in culture. J Neurochem 1995; 64:101-108.
100. Miyamoto M, Ishida M, Kwak S, et al. Agonists for metabotropic glutamate receptors in the rat delay recovery from halothane anesthesia. Eur J Pharmacol 1994; 260:99-102.
101. Henrich-Noack P, Hatton CD, Reymann KG. The mGlu receptor ligand (S)-4C3HPG protects neurons after global ischaemia in gerbils. Neuroreport 1998; 9:985-988.
102. Bond A, O Neill MJ, Hicks CA, et al. Neuroprotective effects of a systemically active group II metabotropic glutamate receptor agonist LY354740 in a gerbil model of global ischaemia. Neuroreport 1998; 9:1191-1193.
103. Bond A, Ragumoorthy N, Monn JA, et al. LY379268, a potent and selective group II metabotropic glutamate receptor agonist, is neuroprotective in gerbil global, but not focal, cerebral ischaemia. Neurosci Lett 1999; 273:191-194.
104. Lam AG, Soriano MA, Monn JA, et al. Effects of the selective metabotropic glutamate agonist LY354740 in a rat model of permanent ischaemia. Neurosci Lett 1998; 254:121-123.
105. Cai Z, Xiao F, Fratkin JD, et al. Protection of neonatal rat brain from hypoxic-ischemic injury by LY379268, a group II metabotropic glutamate receptor agonist. Neuroreport 1999; 10:3927-3931.
106. Klodzinska A, Chojnacka-Wojcik E, Pilc A. Selective group II glutamate metabotropic receptor agonist LY354740 attenuates pentetrazole- and picrotoxin-induced seizures. Pol J Pharmacol 1999; 51:543-545.
107. Klodzinska A, Bijak M, Chojnacka-Wojcik E, et al. Roles of group II metabotropic glutamate receptors in modulation of seizure activity. Naunyn Schmiedebergs Arch Pharmacol 2000; 361:283-288.
108. Allen JW, Ivanova SA, Fan L, et al. Group II metabotropic glutamate receptor activation attenuates traumatic neuronal injury and improves neurological recovery after traumatic brain injury. J Pharmacol Exp Ther 1999; 290:112-120.
109. Pizzi M, Benarese M, Boroni F, et al. Neuroprotection by metabotropic glutamate receptor agonists on kainate-induced degeneration of motor neurons in spinal cord slices from adult rat. Neuropharmacology 2000; 39:903-910.
110. Monyer H, Giffard RG, Hartley DM, et al. Oxygen or glucose deprivation-induced neuronal injury in cortical cell cultures is reduced by tetanus toxin. Neuron 1992; 8:967-973.
111. Bond A, Jones NM, Hicks CA, et al. Neuroprotective effects of LY379268, a selective mGlu2/3 receptor agonist: investigations into possible mechanism of action in vivo. J Pharmacol Exp Ther 2000; 294:800-809.
112. Ciccarelli R, Di Iorio P, Bruno V, et al. Activation of A1 adeNOSine and mGlu3 metabotropic glutamate receptors enhances the release of nerve growth factor and S-100β protein from cultured astrocytes. Glia 1999; 27:275-281.
113. Chao CC, Hu S, Kravitz FH, et al. Transforming growth factor-beta protects human neurons against beta-amyloid-induced injury. Mol Chem Neuropathol 1994; 23:159-178.
114. Prehn JHM, Bindokas VP, Marcuccilli CJ, et al. Regulation of neuronal Bcl-2 protein expression and calcium homeostasis by transforming growth factor type beta confers wide-ranging protection on rat hippocampal neurons. Proc Natl Acad Sci 1994; 91:12599-12603.
115. Prehn JH, Miller RJ. Opposite effects of TGF-beta1 on rapidly- and slowly triggered excitotoxic injury. Neuropharmacology 1996; 35:249-256.
116. Prehn JHM, Bindokas VP, Jordan J, et al. Protective effect of transforming growth factor-β1 on β-amyloid neurotoxicity in rat hippocampal neurons. Mol Pharmacol 1996; 49:319-328.
117. Copani A, Condorelli F, Caruso A, et al. Mitotic signalling by β-amyloid causes neuronal death. FASEB J 1999; 13:2225-2234.
118. Henrich-Noack P, Prehn JH, Krieglstein J. TGF-beta 1 protects hippocampal neurons against degeneration caused by transient global ischemia. Dose-response relationship and potential neuroprotective mechanisms. Stroke 1996; 27:1609-1614.
119. Meucci O, Miller RJ. Gp120-induced neurotoxicity in hippocampal pyramidal neuron cultures: protective action of TGF-beta1. J Neurosci 1996; 16:4080-4088.
120. Tomoda T, Shirasawa T, Yahagi YI, et al. Transforming growth factor-beta is a survival factor for neonate cortical neurons: coincident expression of type-1 receptors in developing cerebral cortices. Dev Biol 1996; 179:79-90.
121. Ren RF, Hawver DB, Kim RS, et al. Transforming growth factor-β protects human hNT cells from degeneration induced by β-amyloid peptide: involvement of the TGF-β type II receptor. Mol Brain Res 1997; 48:315-322.
122. Scorziello A, Florio T, Bajetto A, et al. TGF-β1 prevents gp120-induced impairment of Ca2+ homeostasis and rescues cortical neurons from apoptotic death. J Neurosci Res 1997; 49:600-607.
123. Flanders KC, Ren RF; Lippa CF. Transforming growth factor-betas in neurodegenerative disease. Prog Neurobiol 1998; 54:71-85.
124. Ruocco A, Nicole O, Docagne F, et al. A transforming growth factor-beta antagonist unmasks the neuroprotective role of this endogenous cytokine in excitotoxic and ischemic brain injury. J Cereb Blood Flow Metab 1999; 19:1345-1353.
125. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989; 12:366-375.
126. Konieczny J, Ossowska, K, Wolfarth, et al. LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats. Naunyn-Schmiedebergs Arch. Pharmacol 1998; 358:500-502.
127. Wolfarth S, Konieczny J, Lorenc-Koci E, et al. The role of metabotropic glutamate receptor (mGluR) ligands in parkinsonian muscle rigidity. Amino Acids 2000; 19:95-101.
128. Helton DR, Tizzano JP, Monn JA, et al. LY354740: A metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats. Neuropharmacology 1997; 36:1511-1516.
129. Helton DR, Tizzano JP, Monn JA, et al. Anxiolytic and side-effect profile of LY354740: A potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J Pharmacol Exp Ther 1998; 284:651-660.
130. Vandergriff J, Rasmussen K. The selective mGlu2/3 receptor agonist LY354740 attenuates morphine-withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal. Neuropharmacology 1999; 38:217-222.
131. Popik P, Kozela E, Pilc A. A Selective agonist of group II glutamate metabotropic receptors, LY354740, inhibits tolerance to analgesic effects of morphine in mice. Br J Pharmacol 2000; 130:1425-1431.
132. Shekhar A, Keim SR. LY354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats. Neuropharmacology 2000; 39:1139-1146.
133. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998; 281:1349-1352.
134. Neugebauer V, Zinebi F, Russell R, et al. Cocaine and kindling alter the sensitivity of group II and III metabotropic glutamate receptors in the central amygdala. J Neurophysiol 2000; 84:759-770.
135. Graham ME, Burgoyne RD. Activation of metabotropic glutamate receptors by L-AP4 stimulates survival of rat cerebellar granule cells in culture. Eur J Pharmacol 1994; 288:115-123.
136. Bruno V, Copani A, Bonanno L, et al. Activation of group III metabotropic glutamate receptors is neuroprotective in cortical cultures. Eur J Pharmacol 1996; 310:61-66.
137. Faden AI, Ivanova SA, Yakovlev AG, et al. Neuroprotective effects of group III mGluR in traumatic neuronal injury. J Neurotrauma 1997; 14:885-895.
138. Lafon-Cazal M, Fagni L, Guiraud MJ, et al. mGluR7-like metabotropic glutamate receptors inhibit NMDA-mediated excitotoxicity in cultured mouse cerebellar granule neurons. Eur J Neurosci 1999; 11:663-672.
139. Sabelhaus CF, Schroder UH, Breder J, et al. Neuroprotection against hypoxic/hypoglycaemic injury after the insult by the group III metabotropic glutamate receptor agonist (R, S)-4-phosphonophenylglycine. Br J Pharmacol 2000; 131:655-658.
140. DiFiglia M. Excitotoxic injury of the neostriatum: a model for Huntington s disease. TINS 1990; 13:286-289.
141. Gasparini F, Inderbitzin W, Francotte E, et al. (+)-4-Phosphonophenylglycine (PPG) a new group III selective metabotropic glutamate receptor agonist. Bioorg Med Chem Lett 2000; 10:1241-1244.
142. Pekhletski R, Gerlai R, Oversteet LS, et al. Impaired cerebellar synaptic plasticity and motor performance in mice lacking the mGluR4 subtype of metabotropic glutamate receptor. J Neurosci 1996; 16:6364-6373.
143. Bradley SR, Standaert DG, Rhodes KJ, et al. Immunohistochemical localization of subtype 4a metabotropic glutamate receptors in the rat and mouse basal ganglia. J Comp Neurol 1999; 407:33-46.
144. Kosinski CM, Risso Bradley S, Conn PJ, et al. Localization of metabotropic glutamate receptor 7 mRNA and mGluR7a protein in the rat basal ganglia. J Comp Neurol 1999; 415:266-84.
145. Thomsen C, Hampson DR. Contribution of metabotropic glutamate receptor mGluR4 to L-2-[H-3]amino-4-phosphonobutyrate binding in mouse brain. J Neurochem 1999; 71:835-840.
146. Martin G, Nie Z, Siggins GR. Metabotropic glutamate receptors regulate N-methyl-D-aspartate-mediated synaptic transmission in nucleus accumbens. J Neurophysiol 1997; 78:3028-3038.
147. Maiese K, Vincent A, Lin SH, et al. Group I and group III metabotropic glutamate receptor subtypes provide enhanced neuroprotection. J Neurosci Res 2000; 62:257-272.
148. Doble A. The role of excitotoxicity in neurodegenerative disease: Implications for therapy. Pharmacology & Therapeutics 1999; 81:163-221.
149. Wood PL. NMDA antagonists for stroke and head trauma: current status. Exp Opin Invest Drugs 1998; 7:1505-1508.
150. Abdul-Ghani AS, Attwell PJ, Singh-Kent N, et al. Anti-epileptogenic and anticonvulsant activity of L-2-amino-4-phosphonobutyrate, a presynaptic glutamate receptor agonist. Brain Res 1997; 755:202-212.
151. Chapman AG, Nanan K, Yip P, Meldrum BS. Anticonvulsant activity of a metabotropic glutamate receptor 8 preferential agonist, (R,S)-4-phosphonophenylglycine. Eur J Pharmacol 1999; 383:23-27.
152. Tang E, Yip PK, Chapman AG, et al. Prolonged anticonvulsant action of glutamate metabotropic receptor agonists in inferior colliculus of genetically epilepsy-prone rats. Eur J Pharmacol 1997; 327:109-115.